Abstract Neurological and psychiatric disorders are common in patients with systemic lupus erythematosus (SLE). While several pathogenetic mechanisms are thought to be involved, among of the most challenging and best investigated are antibodies against the N-methyl-D-aspartate (NMDA) receptor subtypes 2a and 2b (anti-NR2 antibodies). This review summarizes the most relevant mechanisms for neuropsychiatric (NP) involvement in SLE (NPSLE) with special emphasis on the role of anti-NR2 antibodies and provides an overview of published articles on anti-NR2 antibodies and brain involvement as of May 2011. In mice, neuronal cell death occurs when anti-NR2 antibodies gain access to the brain, either by injection directly into the brain, or by systemic immunization and abrogation of the blood-brain barrier. Either impaired memory and hippocampal atrophy, or emotional disturbances and atrophy of the amygdala follow, seemingly dependent on the method used for disruption of the bloodbrain barrier. Recent studies indicate that the effect of anti-NR2 antibodies is dose dependent; at low concentrations they alter synaptic function; at higher concentrations they can cause neuronal cell death by apoptosis. An association between anti-NR2 antibodies and NPSLE has been confirmed in 6 out of 13 human studies; the manifestations are primarily of diffuse cerebral character.
Introduction
Systemic lupus erythematosus (SLE) is a disease characterized by multiorgan involvement and numerous immunological abnormalities. In Scandinavian countries, the prevalence of SLE is 60-70 per 100,000 inhabitants, affecting almost ten times more women than men [18, 68] . Common clinical presentations of SLE include arthritis, dermatitis, glomerulonephritis, neurologic manifestations, serositis, blood cytopenias, and thrombosis [17] .
The importance of genetic factors is exemplified by a concordance rate of 24% in monozygotic twins, compared with 2% in dizygotic twins [13] . Specific polymorphic genes coding for molecules involved in important functions of both the innate and the adaptive immune system confer disease susceptibility [23, 26] .
Disruption of immunological tolerance to self, which leads to autoreactive T-and B-cells in predisposed individuals, is fundamental in SLE pathogenesis. Decreased T-cell suppression and polyclonal B-cell activation lead to the production of a variety of autoantibodies, and the formation of immune complexes and complement activation cause inflammation and organ damage. Antibodies against double-stranded DNA (anti-DNA antibodies) are an important marker for SLE. manifestations can be neurological as well as psychological in nature, they are often termed neuropsychiatric SLE (NPSLE). CNS involvement can be diffuse, such as cognitive dysfunction, mood disorders, and psychosis; focal like strokes; or complex, involving both diffuse and focal manifestations. In 1999 the American College of Rheumatology (ACR) proposed case definitions for 19 NPSLE syndromes thought to be relevant manifestations of the disease [3] .
NPSLE manifestations are demonstrated in [50% of SLE patients in most studies; cognitive dysfunction is the most frequent manifestation [5, 9, 10, 33, 73] . SLE can affect all cognitive domains, and cognitive dysfunction is frequently associated with impaired social functioning and work disability [7, 58, 73] .
Most studies have reported no association between the severity of cognitive dysfunction and disease activity [10, 11, 74] . While clinical depression certainly modulates cognitive measures, it is uncertain to what degree cytotoxic drugs and corticosteroids influence cognitive functioning or may give rise to phenomena interpreted as NPSLE [10, 11, 28, 47, 54] .
One possible reason for the reportedly high incidence of NPSLE is the inclusion of NP events not causally related to SLE. Hanly and colleagues, therefore, proposed a classification model that takes into account the association in time between events and the debut of SLE and the presence of other explanatory factors likely to cause or significantly contribute to the development of NP events [30] . They also proposed that phenomena like headaches, anxiety, mild mood disorders, mild cognitive impairment, and polyneuropathy without electrophysiological pathology should be excluded, based on the knowledge that these manifestations are highly prevalent in the non-SLE population [5] . When this model was applied, they found an overall prevalence for NPSLE at the time of SLE diagnosis of 6.1 or 11.7%, depending on whether the phenomena debuted within 6 months (model A) or 10 years (model B) before SLE [30] . A limitation of that study is that structural neuropsychological testing was performed only when cognitive dysfunction was suspected, which may have led to underdiagnosis. Accordingly, the prevalence of cognitive dysfunction in the study (5.4%) was considerably lower than in studies that use formal neuropsychological testing, even when mild impairment was excluded [5, 9] .
The pathogenetic mechanisms behind the wide range of NP manifestations are only beginning to be revealed. Classical autopsy studies demonstrate that brain microinfarcts, microhemorrhages, and small vessel vasculopathy dominate. Other prevalent abnormalities include cortical atrophy, larger infarcts, hemorrhages, and patchy demyelination, while true vasculitis is rare [16, 19, 32, 43] . Signs of neuronal and glial cell damage are evident in the cerebrospinal fluid (CSF) in SLE patients as increased concentrations of glial fibrillary acidic protein (GFAP) and neurofilament triplet protein (NFL) [71] . CSF pleocytosis and oligoclonal immunoglobulin bands are other common abnormalities reflecting intrathecal activation of the immune system [71, 77] , and cerebral MRI reveals cerebral atrophy and white matter hyperintensities in many patients [2, 4] . The mechanisms behind these common findings are unclear.
Certainly, a number of factors affecting both small vascular and brain cellular elements lead to cerebral dysfunction in SLE. One such example is anti-phospholipid antibodies (aPLs), which imply a well-known risk for cerebral and other thromboembolic episodes [34] ; however, in some studies aPLs are also seemingly associated with cognitive dysfunction not due to neuron loss by cerebral infarcts [27, 56] .
Anti-ribosomal P-protein (anti-P) antibodies recognize specific proteins on the ribosomes, and anti-P antibodies detected in blood have been associated with psychosis in some studies [31, 41] , but have not been confirmed in others [44] . An association has been demonstrated between anti-P antibodies in CSF and both complex NPSLE [78] and diffuse NPSLE [36] . In a recent study, Matus and colleagues found P antigens on neuronal cell surfaces in rats, and the injection of anti-P antibodies into rat brains resulted in neuronal apoptosis [52] . Anti-P antibodies are, therefore, likely to be a distinct player in NPSLE pathogenesis. Other possible factors and mechanisms in NPSLE are summarized in Table 1 .
Glutamate is the main excitatory neurotransmitter, and glutamate receptors are widespread throughout the brain. The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor subtype consisting of two NR1 subunits in a complex with two of the four NR2 (a-d) or two NR3 (a and b) subunits [61] . Neurons in the amygdala, anterior hypothalamus, cerebellum, and especially the hippocampus express NMDARs with subunits NR2a and NR2b at high density [60] (Fig. 1) .
The NMDAR forms an ion channel that, at the resting membrane potential, is blocked by Mg 2? [53] . Binding of glutamate and the essential co-agonist glycine, together with sufficient cell membrane depolarization, opens the ion channel, which leads to rapid Ca 2? influx [53] . NMDAR responses mediate survival signals in developing neurons and regulate synaptic strength and neuronal plasticity [51] . In hippocampal cells, NMDAR-gated Ca 2? influx induces long-term potentiation, a process that is fundamental to learning and memory formation [12] .
The NMDAR is also involved in controlling mood and behavior, and hypoactivity of NMDARs is thought to be involved in the pathophysiology of schizophrenia [24] . Psychotropic agents like phencyclidine, dizocilpine, and ketamine noncompetitively inhibit the calcium channel of the NMDAR, leading to behavioral changes that mimic schizophrenia [20] . Prolonged inhibition of the NMDAR by phencyclidine leads to memory loss, thought disturbances, depression, and personality changes [20] . In animals, an increased effect of antidepressant drugs occurs when an NMDAR antagonist is added, which demonstrates the importance of the NMDAR for controlling mood [64] .
Continuous excitatory stimulation of glutamate receptors leads to excessive Ca 2? influx, and eventually cell death [50] . This glutamate excitotoxicity occurs in acute cerebral injuries, such as cerebral ischemia and brain trauma, as well as in neurodegenerative disorders [50] . Ca 2? influx through the NMDAR is more neurotoxic than Ca 2? influx through other ion channels [72] .
Animal studies on the association between anti-NMDAR antibodies and NPSLE Pioneering studies by Diamond et al. [14] demonstrated that a murine monoclonal anti-DNA antibody (R4A) recognized an amino acid sequence (DWEYS) present in both murine and human NR2a and NR2b subunits of the NMDAR. Injecting this antibody into mouse brains led to neuronal death by apoptosis [14] . The cell death occurred without any sign of cerebral inflammation and was thought to be caused by continuous neuronal depolarization and excitation. Likewise, the injection of human SLE sera or CSF containing this antibody into mouse brains resulted in neuronal death [14] . It has recently been demonstrated that the effect of anti-NR2 antibodies is dose dependent; at low concentrations it enhances the intracellular response to agonist binding to the NMDAR, while at higher concentrations it leads to excitotoxic cell death [21] . Some studies indicate that peripherally produced anti-NR2 antibodies must pass through the blood-brain barrier (BBB) to exert an effect upon neurons in the brain. Mice with circulating anti-NR2 antibodies did not show neuronal death by apoptosis before they were injected with the inflammatory provoking agent lipopolysaccharide (LPS) [46] . Abrogation of the BBB by LPS administration led to cell death, predominantly in the hippocampus and impaired memory as measured by behavioral tasks. The same effect was observed after sera from SLE patients and LPS was administered to mice [45] . However, if epinephrine was administered instead of LPS, the mice developed emotional disturbances but no memory impairment [39] . These Hippocampal atrophy, impaired synaptic plasticity and cognition. Increased susceptibility for neuronal loss due to ischemia and excitotoxins [57, 67] experiments, as well as the known roles of NMDARs in memory, learning, mood, and behavior, indicate that anti-NMDAR antibodies (or, more specifically, anti-NR2 antibodies) could be actors in the pathogenesis of NPSLE, likely only after entering the brain through a disrupted BBB and might give rise to specific brain involvement depending on the original insult.
Human studies
As of May 2011, 13 human studies investigating the association between the presence of anti-NR2 antibodies in serum and NPSLE were published; three of these included studies on CSF. Two studies were longitudinal, with 6 months and 5 years follow-up time, while the rest were cross-sectional (Table 2) .
Most studies find anti-NR2 antibodies in blood in approximately one-third of the SLE patients [25, 29, 35, 40, 49, 59 ]. This ratio is higher than revealed in patients with other autoimmune diseases [25, 29, 40, 59, 79] . In addition, anti-NR2 antibodies are found more often in the CSF of SLE patients than in the CSF of patients without autoimmune, neurologic, or psychiatric diseases, and SLE patients with acute CNS manifestations or septic meningitis exhibit higher intrathecal concentrations of anti-NR2 antibodies than SLE patients hospitalized for other reasons [22] . Anti-NR2 antibody levels are, as a rule, higher in blood than in CSF [8, 79] , although the opposite has been reported in patients with complex NPSLE [79] , as well as in those with acute NPSLE with CNS manifestations [22] .
The NR2-reactive antibodies were originally reported to be anti-DNA antibodies. However, it is now clear that there are ''pure'' anti-NR2 antibodies in addition to the originally Fig. 1 The NMDA receptor forms an ion channel with high permeability to Ca 2? ions [60] . The receptor also has extracellular binding sites for the agonist glutamate and its essential co-agonist, glycine [60] . In the resting state, the ion channel is blocked by Mg 2? [53] . Zn 2? can bind to a binding site near the channel and produce a voltage-independent block that modifies the channel gating properties [53] . There is a binding site inside the channel for several NMDAR antagonists, such as phencyclidine, dizocilpine, and ketamine [53] . The cytoplasmic tails of both the NR1 and NR2 subunits are linked to signalling proteins through different scaffolding proteins [65] described anti-DNA antibodies that cross-react with the NMDAR [25, 40, 79] .
Discussion
Although still in its infancy, knowledge about the mechanisms underlying NPSLE is increasing, and anti-NR2
antibodies represent one of the most relevant and investigated types of actors. A number of human studies demonstrate an association between these antibodies and NP manifestations, primarily disturbances of diffuse character [8, 22, 25, 49, 59, 79] . Fundamental immunological and functional animal studies strongly indicate that the observed disturbances are relevant and in accordance with the known function of the NMDAR. However, there are some studies that do not support such conclusions [29, 31, 35, 48, 62, 69] . Disagreement among the human studies may be partly attributable to considerable differences in laboratory and clinical methods applied. Some studies are primarily focused on investigating whether there is an association between anti-NR2 antibodies and cognitive impairment, while others have investigated whether there is a connection between any NP phenomena and the presence of these antibodies. Six studies used formal neuropsychological testing of patients [23, 25, 35, 48, 49, 59, 62] , while in two other studies neuropsychological testing was performed only when cognitive impairment was suspected [29, 69] . Different neuropsychological test batteries were applied: one group used a computer-based neuropsychiatric assessment [62] , and four groups [25, 35, 48, 49 ] used a short neuropsychological test battery proposed by the ACR [3] , while a more extensive battery was used by Omdal et al. [59] .
Furthermore, the ELISA tests employed different plates, peptides, and concentrations of the peptide, serum, and CSF (if tested), as well as different substrates for detection and different cut-off values. Finally, an association between NPSLE and anti-NR2 antibodies has been demonstrated in all studies in which CSF has been examined [8, 22, 79] , while a significant association has been confirmed by only three groups analyzing serum [25, 49, 59] .
It is unclear whether the immune processes are confined to intrathecal regions only (with pathogenetic anti-NR2 antibodies being produced in the brain), or result from antibodies produced in the periphery (requiring an opening of the BBB). Increased permeability of the BBB has been described in SLE patients, especially those with NP manifestations [55, 77] . Thrombotic microvessels, immunemediated activation of endothelium, infection, smoking, and hypertension are all factors that can disrupt the BBB [1, 38, 63] . Reduced levels of anti-NR2 antibodies in CSF were observed in 9 patients who received an intravenous pulse of corticosteroids or were given an increased daily oral corticosteroid dose, indicating less passage of anti-NR2 antibodies through a restored BBB [79] .
Although anti-NR2 antibodies are one of the hottest candidates for NPSLE formation, they can only explain a minor proportion of several phenomena observed in the patients. This may be due to differences in the fine specificity of the antibodies or because some anti-NR2 antibodies show more or less avidity for the antigen. Obviously a number of other mechanisms may be operative in the individual patient and could result in various NP manifestations.
NPSLE contributes considerably to the burden of SLE. Continued efforts to understand the pathogenetic mechanisms behind NPSLE are needed. It is hoped that increased knowledge can lead to improved diagnostics and treatment, and ultimately to better outcomes for SLE patients.
